During the corresponding time, Applied Therapeutics Inc recorded a revenue increase by 719.67 % year on year, While revenue at the Applied Therapeutics Inc 's corporate clients
Applied Therapeutics Inc's Comment on Sales, Marketing and Customers
Customers billing federal programs for products include federal healthcare benefit programs, private third-party payors, Medicaid, and other state programs. Entities involved in the healthcare system comprise healthcare providers, healthcare clearinghouses, health plans, physicians, and teaching hospitals. Under the federal Physician Payments Sunshine Act, manufacturers of drugs, devices, biologics, and medical supplies reimbursed by Medicare, Medicaid, or the Children’s Health Insurance Program are required to report payments or transfers of value to physicians and teaching hospitals. Additionally, applicable manufacturers and group purchasing organizations must disclose ownership and investment interests held by physicians and their immediate family members. Government entities and private litigants have asserted claims against pharmaceutical companies under state consumer protection statutes related to marketing and sales practices.
In recent developments regarding Applied Therapeutics, Inc. (NASDAQ: APLT), legal counsel from the renowned Rosen Law Firm has issued an important reminder to investors concerning impending deadlines related to a securities class action. This update is pertinent for individuals who purchased securities of the biopharmaceutical company during the specified Class Period spanning from January 3, 2024, to December 2, 2024.The Rosen Law Firm, known for its expertise in investor rights, emphasizes the necessity for affected investors to take proactive steps before the significant lead plaintiff deadline of February 18, 2025. Investors seeking to recover potential losses incurred during this period should consider ...
The pharmaceutical landscape is often fraught with high stakes and heightened investor expectations, particularly when it comes to the development of new drugs. In late 2024, Applied Therapeutics, Inc. (NASDAQ: APLT), a company specializing in innovative treatments for serious diseases, found itself embroiled in legal challenges that have significant implications for its reputation and financial stability. Two separate class action lawsuits have been initiated against the company, primarily related to alleged misstatements and failures surrounding its Phase III INSPIRE trial. The Allegations The crux of the allegations is centered on the purported misrepresentation of critical data during Applied Therapeuti...
Navigating New Frontiers in Rare Disease Treatment: Applied Therapeutics Promising Developments Applied Therapeutics Provides Regulatory Updates and Positive Interim Results for Govorestat Late-Cycle Review Meeting with FDA Completed for Govorestat in Treating Classic Galactosemia Applied Therapeutics recently reached an important milestone in its journey to bring Govorestat, a promising treatment for Classic Galactosemia, closer to market approval. The company successfully completed a Late-Cycle review meeting with the U.S. Food and Drug Administration (FDA), signaling a crucial step in the regulatory process. The Late-Cycle Review meeting typically occurs just before the FDA’s target action date, and ...
In recent news, Applied Therapeutics, a clinical-stage biopharmaceutical company, announced an update regarding the New Drug Application (NDA) for govorestat (AT-007), a potential treatment for Classic Galactosemia. The U.S. Food and Drug Administration (FDA) has extended the review period for the NDA by three months, setting a new target action date of November 28, 2024. This development is crucial to patients suffering from Classic Galactosemia, as it brings hope for an effective therapeutic solution. Simultaneously, Applied Therapeutics Inc also witnessed significant growth in revenue during the corresponding period.Extended FDA Review Period for Govorestat:Applied Therapeutics govorestat has demonstrate...
In the field of pharmaceutical sciences, continuous research and development efforts to find better treatment options for rare genetic disorders have led to significant advancements. In this context, Applied Therapeutics Inc has recently announced positive results from a 12-month interim analysis of Govorestat (AT-007) in their ongoing INSPIRE Phase 3 Trial for Sorbitol Dehydrogenase (SORD) Deficiency. These findings highlight the potential of Govorestat as a breakthrough therapy for patients suffering from this rare genetic disorder.Factual Interpretation:During the ongoing INSPIRE Phase 3 Trial, Applied Therapeutics Inc reported that the interim primary endpoint has been successfully met. This indicates th...
Applied Therapeutics Inc’s Comment on Sales, Marketing and Customers
Customers billing federal programs for products include federal healthcare benefit programs, private third-party payors, Medicaid, and other state programs. Entities involved in the healthcare system comprise healthcare providers, healthcare clearinghouses, health plans, physicians, and teaching hospitals. Under the federal Physician Payments Sunshine Act, manufacturers of drugs, devices, biologics, and medical supplies reimbursed by Medicare, Medicaid, or the Children’s Health Insurance Program are required to report payments or transfers of value to physicians and teaching hospitals. Additionally, applicable manufacturers and group purchasing organizations must disclose ownership and investment interests held by physicians and their immediate family members. Government entities and private litigants have asserted claims against pharmaceutical companies under state consumer protection statutes related to marketing and sales practices.
Sources:
Applied Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Applied Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Applied Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
